Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
01 nov. 2021 07h30 HE
|
Junshi Biosciences
SHANGHAI, China and REDWOOD CITY, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19
19 sept. 2021 07h29 HE
|
Junshi Biosciences
SHANGHAI, China, Sept. 19, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
16 sept. 2021 20h19 HE
|
Junshi Biosciences
– Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 – – Data support the use of toripalimab with chemotherapy as first-line therapy...
Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
15 sept. 2021 08h30 HE
|
Junshi Biosciences
SHANGHAI and REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”,...
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
13 sept. 2021 20h55 HE
|
Junshi Biosciences
SHANGHAI, China and REDWOOD CITY, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc....
Junshi Biosciences and Coherus Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
01 sept. 2021 08h00 HE
|
Junshi Biosciences
SHANGHAI, China and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc....
Junshi Biosciences Announces 2021 Interim Financial Results and Provides Corporate Updates
30 août 2021 19h30 HE
|
Junshi Biosciences
SHANGHAI, China, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
Distribution of Etesevimab/JS016 in the US Reopened
29 août 2021 08h03 HE
|
Junshi Biosciences
SHANGHAI, China, Aug. 29, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody
26 août 2021 19h30 HE
|
Junshi Biosciences
SHANGHAI, China, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
18 août 2021 21h09 HE
|
Junshi Biosciences
– Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone – - Data support the use of toripalimab with chemotherapy as first-line...